11 Einträge gefunden

1. Plain language summary of the MAIA study of daratumumab plus lenalidomide and dexamethasone for the treatment of people with newly diagnosed multiple myeloma

   1. Facon, Thierry
   2. Kumar, Shaji K
   3. Plesner, Torben
   4. Orlowski, Robert Z
   5. Moreau, Philippe
   6. Bahlis, Nizar
   7. Basu, Supratik

   2023 - Forschungsinformationssystem des UKE - frei zugänglich
2. Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA

   1. Facon, Thierry
   2. Cook, Gordon
   3. Usmani, Saad Z
   4. Hulin, Cyrille
   5. Kumar, Shaji
   6. Plesner, Torben
   7. Touzeau, Cyrille

   2022 - Forschungsinformationssystem des UKE - frei zugänglich
3. Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): a multicentre, multicohort, open-label, phase 1/2 trial

   1. Lonial, Sagar
   2. Popat, Rakesh
   3. Hulin, Cyrille
   4. Jagannath, Sundar
   5. Oriol, Albert
   6. Richardson, Paul G
   7. Facon, Thierry

   2022 - Forschungsinformationssystem des UKE
4. Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network

   1. Ludwig, Heinz
   2. Boccadoro, Mario
   3. Moreau, Philippe
   4. San-Miguel, Jesus
   5. Cavo, Michele
   6. Pawlyn, Charlotte
   7. Zweegman, Sonja

   2021 - Forschungsinformationssystem des UKE - frei zugänglich
5. Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial

   1. Facon, Thierry
   2. Kumar, Shaji K
   3. Plesner, Torben
   4. Orlowski, Robert Z
   5. Moreau, Philippe
   6. Bahlis, Nizar
   7. Basu, Supratik

   2021 - Forschungsinformationssystem des UKE
6. Front-line daratumumab-VTd versus standard-of-care in ASCT-eligible multiple myeloma: matching-adjusted indirect comparison

   1. Moreau, Philippe
   2. Hebraud, Benjamin
   3. Facon, Thierry
   4. Leleu, Xavier
   5. Hulin, Cyrille
   6. Hashim, Mahmoud
   7. Hu, Yannan

   2021 - Forschungsinformationssystem des UKE
7. COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network

   1. Ludwig, Heinz
   2. Sonneveld, Pieter
   3. Facon, Thierry
   4. San-Miguel, Jesus
   5. Avet-Loiseau, Hervé
   6. Mohty, Mohamad
   7. Mateos, Maria-Victoria

   2021 - Forschungsinformationssystem des UKE - frei zugänglich
8. Carfilzomib, dexamethasone and daratumumab in relapsed or refractory multiple myeloma: results of the phase III study CANDOR by prior lines of therapy

   1. Quach, Hang
   2. Nooka, Ajay
   3. Samoylova, Olga
   4. Venner, Christopher P
   5. Kim, Kihyun
   6. Facon, Thierry
   7. Spencer, Andrew

   2021 - Forschungsinformationssystem des UKE - frei zugänglich
9. Health-Related Quality of Life in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: Findings From the Phase III MAIA Trial

   1. Perrot, Aurore
   2. Facon, Thierry
   3. Plesner, Torben
   4. Usmani, Saad Z
   5. Kumar, Shaji
   6. Bahlis, Nizar J
   7. Hulin, Cyrille

   2021 - Forschungsinformationssystem des UKE - frei zugänglich
10. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial

    1. Richardson, Paul G
    2. Oriol, Albert
    3. Beksac, Meral
    4. Liberati, Anna Marina
    5. Galli, Monica
    6. Schjesvold, Fredrik
    7. Lindsay, Jindriska

    2019 - Forschungsinformationssystem des UKE
11. Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma

    1. Facon, Thierry
    2. Kumar, Shaji
    3. Plesner, Torben
    4. Orlowski, Robert Z
    5. Moreau, Philippe
    6. Bahlis, Nizar
    7. Basu, Supratik

    2019 - Forschungsinformationssystem des UKE